Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights March 30, 2026 PDF Version Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across…
2024-03-27 Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer(Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer) Strong…
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Mar. 15, 2023– Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company…
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Mar. 15, 2023– Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company…
May 11, 2026 PDF Version Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ:…
2024-05-09 Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE)…
